<DOC>
	<DOCNO>NCT00238004</DOCNO>
	<brief_summary>Abnormal blood cholesterol level increase risk develop , die heart disease . It well recognise `` harmful '' LDL cholesterol high , `` protective '' HDL cholesterol low , risk increase . Drugs call statin routinely use patient heart disease , well tolerate , decrease harmful LDL cholesterol level . However , statins increase protective HDL cholesterol small extent . Some patient may thus benefit additional medication increase protective HDL-cholesterol . One effective drug nicotinic acid . This drug well establish available 30 year . Previous use limit facial flush large percentage patient receive drug . However new formulation call Niaspan available associate much less flush . Although many patient transient flushing , estimate 1 patient every 20 receive drug discontinue treatment . We therefore propose , patient coronary artery disease low HDL cholesterol despite statin , study effect Niaspan HDL cholesterol lipid parameter , assess tolerability .</brief_summary>
	<brief_title>The Low HDL On Six Weeks Statin Therapy ( LOW ) Study</brief_title>
	<detailed_description>Objective : To assess , patient coronary heart disease low HDL-cholesterol , efficacy tolerability Niaspan adjunct statin therapy clinical practice . Background : Despite clear reduction mortality cardiovascular morbidity associate reduction LDL cholesterol ( LDL-C ) statin therapy , sizeable proportion patient remain risk subsequent adverse cardiac event [ 1-3 ] . It clear patient , risk reduction may obtain address element lipid profile . In particular , sub-analysis Framingham study show give level LDL-C , risk coronary heart disease event decrease increase HDL cholesterol ( HDL-C ) level [ 4 ] . In addition , adverse cardiac risk associate elevate triglyceride predominantly see patient low HDL-C level [ 5 ] . The protective effect HDL-C appear predominantly mediate via reverse cholesterol transport . In process , excess cholesterol cell membrane transfer HDL-C peripheral tissue , cholesterol convert cholesteryl ester HDL-C lecithin : cholesterol acyltransferase ( LCAT ) , newly synthesize cholesteryl ester transport HDL-C low density lipoproteins action cholesteryl ester transfer protein ( CETP ) finally , cholesterol remove plasma hepatic clearance plasma lipoproteins . Of available licensed lipid lower agent , nicotinic acid great potential raise HDL-C , addition give favourable reduction LDL-C , triglyceride , lipoprotein ( ) , apolipoprotein B-100 elevation Apolipoprotein A-1 . Early study nicotinic acid confirm efficacy improve cardiac outcome . The Coronary Drug Project [ 6 ] , study 8341 men previous MI . A 26 % reduction non fatal MI 24 % reduction cerebrovascular event report 6 year follow [ 6 ] 11 % reduction mortality 15 year follow [ 7 ] . The Stockholm Ischemic Heart Disease Secondary Prevention Study [ 8 ] compare niacin plus clofibrate vs. placebo 555 post MI survivors 5 year report 26 % reduction overall mortality ( p &lt; 0.05 ) 36 % reduction CHD mortality ( p &lt; 0.01 ) . In current era , statin therapy consider mandatory patient confirm coronary artery disease [ 3 ] . However , nicotinic acid appear safe efficacious combination statin therapy demonstrate recent HDL Atherosclerosis Treatment Study ( HATS ) [ 9 ] , frequency composite end point ( death , MI , stroke , revascularization ) reduce 24 % placebo 3 % simvastatin-niacin therapy . While flush previously use limit factor immediate release nicotinic acid ( niacin ) , new extend release preparation ( Niaspan ) reduce incidence use limit flush &lt; 6 % . Several study demonstrate ability Niaspan improve HDL level , either monotherapy [ 10,11 ] , addition statin therapy [ 12 ] . To date safety efficacy Niaspan study placebo control manner , group patient coronary artery disease already statin therapy . Study population : Patients recruit primarily cardiology ward Craigavon Cardiac Centre , Craigavon Area Hospital . Inclusion criterion : 1 . Persisting low HDL-C ( &lt; 0.9mmol/l ) full lipid profile result ( inpatient take &lt; 24 hour admission ) . 2 . Objective diagnosis coronary heart disease ( previous biomarker proven MI , positive stress test , angiogram least one &gt; 50 % diameter stenosis ) 3 . Established least 6 week “ maintenance ” dose statin therapy ( define Pravastatin 40mg , Simvastatin 40mg Atorvastatin ≥10mg ) . The dose type statin alter study period 4 . Absence concurrent major systemic illness ( particularly liver renal failure , hypo hyperthyroidism ) Exclusion criterion : 1 . Previous use Niaspan non-statin lipid lowering agent within previous 12 week 2 . Contraindications Niaspan therapy 3 . Participation another medical trial within previous 30days 4 . Failure obtain informed consent Study Design : To consider pilot study . Patients prospectively randomize , double blind fashion 1:1 ratio , receive Niaspan otherwise identical placebo , dos titrate accord clinical response . The primary outcome measure number patient achieve target HDL-C level ( define HDL-C &gt; 1.0mmol/l male &gt; 1.29mmol/l female ) completion study protocol take Niaspan compare placebo . The final HDL-C blood sample comparative analysis group take week 11 , week 15 , HDL-C target reach week 11 . Given HDL-C inclusion criterion &lt; 0.9mmol/l , assume least difference detect 0.09mmol , allow study drop out , 30 patient per group &gt; 90 % power detect difference statistically significant . Analysis intention treat make independent sample T test . References 1 . Randomised trial cholesterol lower 4444 patient coronary heart disease : Scandinavian Simvastatin Survival Study ( 4S ) Lancet 1994 ; 344:1383-9 . 2 . LIPID Study Investigators . Long-term risk stratification survivor acute coronary syndrome . Results Long-term Intervention Pravastatin Ischemic Disease ( LIPID ) Study . J Am Coll Cardiol 2001 ; 38:56-63 . 3 . MRC/BHF Heart Protection Study cholesterol-lowering simvastatin 5963 people diabetes : randomise placebo-controlled trial . Lancet 2003 ; 361:2005-16 . 4 . Castelli WP , Anderson K , Wilson PW , Levy D. Lipids risk coronary heart disease . The Framingham Study . Ann Epidemiol 1992 ; 2 ( 1-2 ) :23-8 . 5 . Gordon T , Castelli WP , Hjortland MC , Kannel WB , Dawber TR . High density lipoprotein protective factor coronary heart disease . The Framingham Study . Am J Med 1977 ; 62:707-14 6 . Gans DJ . Coronary Drug Project JAMA 1975 ; 234:21-2 7 . Canner PL , Berge KG , Wenger NK , Stamler J , Friedman L , Prineas RJ , Friedewald W. Fifteen year mortality Coronary Drug Project patient : long-term benefit niacin . J Am Coll Cardiol 1986 ; 8:1245-55 . 8 . Carlson LA , Rosenhamer G. Reduction mortality Stockholm Ischaemic Heart Disease Secondary Prevention Study combine treatment clofibrate nicotinic acid . Acta Med Scand . 1988 ; 223 ( 5 ) :405-18 . 9 . Brown BG , Zhao XQ , Chait A , Fisher LD , Cheung MC , Morse JS , Dowdy AA , Marino EK , Bolson EL , Alaupovic P , Frohlich J , Albers JJ . Simvastatin niacin , antioxidant vitamin , combination prevention coronary disease . N Engl J Med . 2001 Nov 29 ; 345 ( 22 ) :1583-92 . 10 . Capuzzi DM , Guyton JR , Morgan JM , Goldberg AC , Kreisberg RA , Brusco OA , Brody J. Efficacy safety extended-release niacin ( Niaspan ) : long-term study . Am J Cardiol 1998 ; 8274U-81U . 11 . Morgan JM , Capuzzi DM , Guyton JR. A new extended-release niacin ( Niaspan ) : efficacy , tolerability , safety hypercholesterolemic patient . Am J Cardiol 1998 ; 82:29U-34U . 12 . Wolfe ML , Vartanian SF , Ross JL , Bansavich LL , Mohler ER 3rd , Meagher E , Friedrich CA , Rader DJ . Safety effectiveness Niaspan add sequentially statin treatment dyslipidemia . Am J Cardiol 2001 ; 87 ( 4 ) :476-9 , A7 . 13 . Third Report National Cholesterol Education Program ( NCEP ) Expert Panel Detection , Evaluation , Treatment High Blood Cholesterol Adults ( Adult Treatment Panel III ) final report . Circulation 2002 ; 106 ( 25 ) :3143-421 . 14 . Mosca L , et al . AHA scientific statement . Evidence-based guideline cardiovascular disease prevention woman . Circulation . 2004 ; 109:672-693 .</detailed_description>
	<mesh_term>Arteriosclerosis</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Nicotinic Acids</mesh_term>
	<mesh_term>Niacin</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Persisting low HDLC ( &lt; 0.9mmol/l ) full lipid profile result ( inpatient take &lt; 24 hour admission ) . Objective diagnosis coronary heart disease ( previous biomarker proven MI , positive stress test , angiogram least one &gt; 50 % diameter stenosis ) Established least 6 week “ maintenance ” dose statin therapy ( define Pravastatin 40mg , Simvastatin 40mg Atorvastatin ≥10mg ) . The dose type statin alter study period Absence concurrent major systemic illness ( particularly liver renal failure , hypo hyperthyroidism ) Previous use Niaspan nonstatin lipid lowering agent within previous 12 week Contraindications Niaspan therapy Participation another medical trial within previous 30days Failure obtain informed consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2006</verification_date>
	<keyword>Niacin</keyword>
</DOC>